Drug Target Review

FEBRUARY 19, 2024

In the early days of my biopharma career, I was able to industrialise the production of recombinant proteins for drug discovery purposes, by parallelising, miniaturising and automating protein expression and purification workflow. This made significant impact on accelerating lead discovery in the pharmaceutical industry.

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

Drug Target Review

JULY 5, 2023

This selectable marker enables the identification of cells which have taken up the GOIs and aids the initial selection of recombinant protein expressing cell lines. A potential future for host cell lines There have been many recent advances in cell line engineering technologies and our understanding of CHO cells.

Engineering 105

Engineering DNA Laboratories Production 105

Codon

DECEMBER 10, 2023

A zoologist, ecologist, and protein engineer all call themselves “biologists,” but rarely attend the same conferences. Align to Innovate’s Open Datasets Initiative (one of us, Erika DeBenedictis, is the founder) roadmaps high-impact datasets in biology, and then hires automation engineers to collect them.

Protein Expression 69

Protein Expression DNA Laboratories Engineering 69

Advarra

JANUARY 11, 2024

One strategy proposed the use of synthetic mRNA or modified mRNA analogs, which can enhance the stability and protein expression of mRNA. Monoclonal Antibodies Monoclonal antibodies are lab-engineered immune system proteins.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

Broad Institute

SEPTEMBER 5, 2024

In recent years, increasingly sensitive mass spectrometers have paved the way for enormous progress: scientists are now able to detect and analyze nearly all proteins expressed in a sample, including ones present only in miniscule amounts. They're engineering problems that we just need to find a solution to.

Disease 80

Disease Protein Expression Engineering Treatment 80

Codon

APRIL 9, 2023

LanzaTech announced a partnership with H&M Move to convert factory carbon emissions into fabrics using engineered microbes. Sponge cells double in population quite quickly — around 40 minutes — and could be engineered to manufacture drugs. Read Biological Engineering *Self-healable spider dragline silk materials.

Therapies 52

Therapies RNA Engineering Vaccine 52

The Pharma Data

DECEMBER 8, 2020

The company’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. co-founder, president and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence. .

RNA 52

RNA Therapies Disease Protein Expression 52

Drug Target Review

SEPTEMBER 10, 2024

Advances in new technologies such as engineer transposase-based semi-targeted transgene integration, which integrates the genes of interest into highly active regions of the host genome, have enabled the generation of consistently and predictably high-yielding cell lines, as well as, supporting rapid stable pool generation.

Drug Development 64

Drug Development Clinical Supply Production Protein Expression 64

The Pharma Data

AUGUST 16, 2021

The vaccine candidate, presently at a preclinical development stage, is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs).

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 13, 2021

TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. Second generation anti-CD40-ligand mAbs had dramatically reduced binding to Fc?RII,

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 10, 2021

ILP100 is a genetically engineered Lactobacillus that acts as a small bioreactor on site in the wound, continuously introducing a chemokine, CXCL12, into the wound tissue. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression.

Clinical Trials 52

Clinical Trials Trials FDA Vaccine 52

The Pharma Data

JUNE 7, 2023

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Rahway, NJ, USA), an anti-PD-1 therapy.

Trials 40

Trials Protein Expression Therapies Treatment 40

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

The Pharma Data

OCTOBER 26, 2020

Increased infiltrates, expression of immune related genes and higher PD-L1 protein expression were observed across all patients suggesting a remodeling of the tumor microenvironment consistent with a switch toward a “hot tumor” phenotype. Conclusions. About TG4001.

Vaccine 40

Vaccine Trials Treatment Virus 40

The Pharma Data

AUGUST 9, 2021

We believe this highly sophisticated and specifically engineered ADC is fulfilling its promise to reshape the treatment of HER2-positive metastatic breast cancer, with the goal to move into earlier lines of treatment for HER2-positive breast cancer and many other HER2-expressing tumour types across our broad clinical trial programme.”.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52